U.S. Markets closed

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
143.53-0.59 (-0.41%)
At close: 4:00PM EDT

Alnylam Pharmaceuticals, Inc.

675 West Kendall Street
Cambridge, MA 02142
United States
617 551 8200
http://www.alnylam.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees1,323

Key Executives

NameTitlePayExercisedYear Born
Dr. John M. MaraganoreCEO & Exec. Director1.79M5.77M1963
Mr. Barry E. GreenePres1M4.27M1963
Mr. Jeffrey V. PoultonExec. VP, CFO and Principal Financial & Accounting Officer681.75kN/A1968
Dr. Yvonne L. Greenstreet M.B.A., MBChB, MBAChief Operating Officer1.14M453.27k1963
Dr. Akshay K. VaishnawPres of R&D986.1kN/A1963
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). In addition, the company is developing givosiran for the treatment of patients with AHP; lumasiran for the treatment of primary hyperoxaluria type 1, or PH1; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc., as well as collaboration with Vir Biotechnology, Inc. to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. It also has a collaboration and license agreement with Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational ribonucleic acid interference therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, as well as Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Alnylam Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 8, 2019 is 4. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 6; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.